Correlation Between Pre-collection Lympho-mononuclear Cell Count and CD34+ Cell Yield in Peripheral Blood Stem Cell Collection: A Single-center Experience from Sunpasitthiprasong Hospital

Pavarit Arayasukawat

doi:10.64960/srimedj.v41i3.270843

Authors

Pavarit Arayasukawat Department of Blood Banking and Transfusion Medicine, Sunpasitthiprasong Hospital, Ubon Ratchathani, Thailand 34000

DOI:

https://doi.org/10.64960/srimedj.v41i3.270843

Keywords:

peripheral blood stem cell collection, pre-collection predictor, lympho-mononuclear cell, absolute neutrophil count, yield of CD34+ cell

Abstract

Background and objective: Peripheral blood stem cell (PBSC) collection is resource-intensive, highlighting the need for reliable and widely available predictive markers to optimize collection efficiency. Although pre-collection CD34⁺ cell count is an established predictor, the potentiality is limited in curtains laboratories. This study evaluated the association of pre-collection lympho-mononuclear cell (MNC) count and absolute neutrophil count (ANC) with PBSC yield.

Methods: This study conducted a retrospective analysis of 52 patients undergoing autologous PBSC collection at Sunpasitthiprasong Hospital between 2013 and 2025. Correlations between pre-collection MNC, ANC, CD34⁺ cell count and PBSC yield were assessed, followed by log-transformed multivariable regression to identify independent predictors.

Results: PBSC yield correlated strongly with pre-collection CD34⁺ cell count (r = 0.87, p < 0.001) and moderately with MNC (r = 0.46, p < 0.001), while ANC showed no significant association. In multivariable analysis, only pre-collection CD34⁺ cell count remained an independent predictor.

Conclusion: Pre-collection MNC shows a moderate association with PBSC yield; however, CD34⁺ cell count remains the most robust predictor for optimizing PBSC collection.

References

Orkin SH, Zon LI. Hematopoiesis: an evolving paradigm for stem cell biology. Cell 2008;132(4):631-44. doi:10.1016/j.cell.2008.01.025 .

Weissman IL. Stem cells. Cell 2000;100(1):157-68. doi:10.1016/S0092-8674(00)81692-X.

Doulatov S, Notta F, Laurenti E, Dick JE. Hematopoiesis: a human perspective. Cell Stem Cell 2012;10(2):120. doi:10.1016/j.stem.2012.01.006.

Krause D, Fackler M, Civin C, May W. CD34: structure, biology, and clinical utility. Blood 1996;87(1):1-13. doi:10.1182/blood.V87.1.1.1.

Thomas ED, Lochte HL, Lu WC, Ferrebee JW. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 1957;257(11):491-6. doi:10.1056/NEJM195709122571102.

Appelbaum FR. Hematopoietic-cell transplantation at 50. N Engl J Med 2007;357(15):1472-5. doi:10.1056/NEJMp078166.

Passweg JR, Halter J, Bucher C, Gerull S, Heim D, Rovó A, et al. Hematopoietic stem cell transplantation: a review and recommendations for follow-up care for the general practitioner. Swiss Med Wkly 2012;142(4142):w13696. doi:10.4414/smw.2012.13696.

Gratwohl A, Pasquini MC, Aljurf M, Atsuta Y, Baldomero H, Foeken L, et al. One million haemopoietic stem-cell transplants: a retrospective observational study. Lancet Haematol 2015;2(3):e91-e100. doi:10.1016/S2352-3026(15)00028-9.

Gahrton G, Iacobelli S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, et al. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood 2013;121(25):5055-63. doi:10.1182/blood-2012-11-469452.

Passweg JR, Baldomero H, Chabannon C, Basak GW, Corbacioglu S, Duarte RF, et al. The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T’s come into focus. Bone Marrow Transplant 2020;55(8):1604-13. doi:10.1038/s41409-020-0826-4.

Hosing C, Smith VR, Rhodes BA, Walters KH, Qazilbash MH, McMannis JD, et al. An analysis of the costs associated with peripheral blood hematopoietic progenitor cell mobilization, collection and cryopreservation in patients with lymphomas undergoing autologous stem cell transplantation. Blood 2008;112(11):2377. doi:10.1182/blood.V112.11.2377.2377.

Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-hodgkin’s lymphoma. N Engl J Med 1995;333(23):1540-5. doi:10.1056/NEJM199512073332305.

Samara Y, Mei M. Autologous stem cell transplantation in Hodgkin lymphoma-latest advances in the era of novel therapies. Cancers 2022;14(7):1738. doi:10.3390/cancers14071738.

Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13- cis -retinoic acid. N Engl J Med 1999;341(16):1165-73. doi:10.1056/NEJM199910143411601.

Żebrowska U, Balwierz W, Wechowski J, Wieczorek A. Survival benefit of myeloablative therapy with autologous stem cell transplantation in high-risk neuroblastoma: a systematic literature review. Target Oncol 2024;19(2):143-59. doi:10.1007/s11523-024-01033-4.

Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet G, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335(2):91-7. doi:10.1056/NEJM199607113350204.

Hosing C, Saliba RM, Hamerschlak N, Kutner JN, Sakashita AM, Kondo AT, et al. Peripheral blood stem cell yield calculated using preapheresis absolute CD 34+ cell count, peripheral blood volume processed, and donor body weight accurately predicts actual yield at multiple centers. Transfusion (Paris) 2014;54(4):1081-7. doi:10.1111/trf.12435.

Sinha S, Gastineau D, Micallef I, Hogan W, Ansell S, Buadi F, et al. Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. Bone Marrow Transplant 2011;46(7):943-9. doi:10.1038/bmt.2010.236.

Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematother 1996;5(3):213-26. doi:10.1089/scd.1.1996.5.213.

Keeney M, Chin-Yee I, Weir K, Popma J, Nayar R, Sutherland DR. Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelines. International Society of Hematotherapy and Graft Engineering. Cytometry 1998;34(2):61-70. doi:10.1002/(sici)1097-0320(19980415)34:2<61::aid-cyto1>3.0.CO;2-f.

Cousins AF, Sinclair JE, Alcorn MJ, Green HA, Douglas KW. HPC‐A dose prediction on the optia® cell separator based on a benchmark CE2 collection efficiency: promoting clinical efficiency, minimizing toxicity, and allowing quality control. J Clin Apheresis 2015;30(6):321-8. doi:10.1002/jca.21380.

Asthana B, Dubey R, Kaur A, Pawar A, Biswas A. Evaluating the role of mononuclear cell count in predicting the cell dose of apheresis-derived peripheral blood stem cells by correlating with flow cytometry-based CD34 enumeration. Int J Sci Res 2018;7(12):72-4. doi:10.36106/ijsr.

Krishnamurthy PK, Sarathy V, Jayappa SB, Badarkhe GV, Kumar KSR, Thianeshwaran S, et al. Study of peripheral mononuclear cells and CD34 levels as a predictive marker for initiating apheresis in autologous stem cell transplant. Int J Hematol-Oncol Stem Cell Res 2021;15(3):170-7. doi:10.18502/ijhoscr.v15i3.6847.

Tiwari A, Pandey P, Subbaraman H, Bhargava R, Rawat G, Madiraju S, et al. Autologous peripheral blood stem cell harvest: collection efficiency and factors affecting it. Asian J Transfus Sci 2016;10(1):93-7. doi:10.4103/0973-6247.164273.

Rujkijyanont P, Hipps J, Gan K, Yang J, Wang C, Geiger TL, et al. Prediction of CD34 + cell yield in hematopoietic cell products from children by peripheral blood CD34 + cell counts. Cytotherapy 2012;14(4):473-9. doi:10.3109/14653249.2011.652734.

Thulasiraman R, Vaidhyanathan L, Muthu A, Prabhakar V, Ramakrishnan B, Raj R, et al. Simple predictors of peripheral blood stem cell yield in healthy donors: a retrospective analysis in a tertiary care hospital. J Appl Hematol 2021;12(1):31-6. doi:10.4103/joah.joah_100_20.

Semerad CL, Christopher MJ, Liu F, Short B, Simmons PJ, Winkler I, et al. G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. Blood 2005;106(9):3020-7. doi:10.1182/blood-2004-01-0272.

Kim HK, De La Luz Sierra M, Williams CK, Gulino AV, Tosato G. G-CSF down-regulation of CXCR4 expression identified as a mechanism for mobilization of myeloid cells. Blood 2006;108(3):812-20. doi:10.1182/blood-2005-10-4162.

Christopher MJ, Liu F, Everly N, Link DC. Disruption of SDF-1/CXCR4 signaling during Flt-3 ligand and stem cell factor (SCF) induced hematopoietic progenitor mobilization. Blood 2004;104(11):4139. doi:10.1182/blood.V104.11.4139.4139.

Yu J, Leisenring W, Bensinger WI, Holmberg LA, Rowley SD. The predictive value of white cell or CD34+ cell count in the peripheral blood for timing apheresis and maximizing yield. Transfusion (Paris) 1999;39(5):442-50. doi:10.1046/j.1537.1999.39050442.x.

Steussy BW, Capper M, Krasowski MD, Rosenthal NS, Schlueter AJ. Algorithms utilizing peripheral blood hematopoietic progenitor cell counts in lieu of some CD 34+ cell counts predict successful peripheral blood stem cell collections with substantial time and cost savings. ISBT Sci Ser 2016;11(3):153-62. doi:10.1111/voxs.12289.

Sohn SK, Kim JG, Chae YS, Kim DH, Lee NY, Suh JS, et al. Large‐volume leukapheresis using femoral venous access for harvesting peripheral blood stem cells with the Fenwal CS 3000 Plus from normal healthy donors: predictors of CD34+ cell yield and collection efficiency. J Clin Apheresis 2003;18(1):10-5. doi:10-5.1002/jca.10044.

Sutherland DR, Keeney M, Gratama JW. Enumeration of CD 34+ hematopoietic stem and progenitor cells. Curr Protoc Cytom 2003;25(1):6.4.1–6.4.23. doi:10.1002/0471142956.cy0604s25.

Sanderson F, Poullin P, Smith R, Nicolino-Brunet, Philip P, Chaib A, et al. Peripheral blood stem cells collection on spectra optia apheresis system using the continuous mononuclear cell collection protocol: A single center report of 39 procedures. J Clin Apheresis 2017;32(3):182-90. doi:10.1002/jca.21485.